Cipla Limited has announced that its wholly owned US subsidiary will recall unexpired batches of Lanreotide Injection, leading to a temporary supply disruption in the market. The pharmaceutical major disclosed this development under regulatory compliance requirements on 9th March, 2026.

Recall Details and Timeline

The recall decision by Cipla USA Inc. follows extensive discussions with Pharmathen International S.A. This latest disclosure continues a series of communications that began earlier this year, with previous intimations filed on 7th January, 2026, 14th January, 2026, and 21st February, 2026.

Regulatory Compliance

The company filed this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Rajendra Chopra signed the regulatory filing, ensuring compliance with stock exchange requirements across multiple jurisdictions including BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg.

Market Supply Impact

The recall of unexpired Lanreotide Injection batches will result in a temporary lack of supply to the market. Lanreotide is typically used for treating certain hormonal disorders, and the supply disruption may affect patients dependent on this medication until alternative arrangements are made.

The pharmaceutical company has maintained transparency throughout this process, providing regular updates to stakeholders and regulatory authorities as the situation develops. The recall represents a precautionary measure to ensure patient safety and product quality standards.

Cipla has announced the formation of a strategic joint venture with Kemwell Biopharma Private Limited, marking a significant expansion into the biologics segment. The partnership represents a major investment commitment with both companies planning to invest up to ₹100 million in their respective ownership ratios.

Joint Venture Structure

The companies have established a 60:40 partnership arrangement for incorporating a joint venture company in India:

Strategic Partnership Details

Both partners will invest up to ₹100 million in the joint venture company according to their respective ownership ratios. This substantial investment commitment reflects the strategic importance of the biologics segment for both companies.

The joint venture will undertake comprehensive biologics operations including developing, applying for and obtaining licenses, manufacturing, commercializing, importing and exporting biologic products, as well as licensing or outsourcing these activities.

Partner Capabilities

Kemwell Biopharma brings significant expertise as a premier Asia-based biologics Contract Development and Manufacturing Organization (CDMO). The company operates an end-to-end service platform for global biopharma clients through its Bangalore cGMP site, which is certified by the US FDA.

Business Objectives

The joint venture company is being incorporated with the objective to develop, manufacture and commercialize biologics for global markets. This collaboration positions both partners to capitalize on the growing biologics market segment by combining Cipla's established pharmaceutical market presence with Kemwell's specialized biologics manufacturing capabilities.

Kemwell supports both commercial manufacturing and research and development programs for novel biologics and biosimilars, making it an ideal partner for Cipla's biologics expansion strategy.